Category: Treatment Updates

OPDIVO™ is the first immuno-oncology therapy for lung cancer in Canada to use the body's own immune system to fight cancer MONTREAL, June 8, 2016 /CNW/ – Canada's national health technology assessment body (CADTH) today made its final, positive recommendation for OPDIVO™ (nivolumab) for the treatment of non-small cell lung cancer (NSCLC), a reflection of the strong clinical evidence that supports the benefits of this immuno-oncology treatment of adult patients

Hot from the press, BMS just received the final pCODR recommendation for Opdivo in lung cancer. PERC has maintained its initial recommendation with no change. This is an excellent news for the patients. See the information on pCODR website.   Have a great Friday afternoon and a good ASCO Louise!   Sabrina   https://www.cadth.ca/opdivo-non-small-cell-lung-cancer-details    

KIRKLAND, QC, May 31, 2016 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. KEYTRUDA is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status. "We are excited to share this announcement with

Introduction: Febrile neutropenia, or FN, is a common and potentially serious side effect of chemotherapy treatment. Neutrophils are a type of white blood cell responsible for helping fight germs and infections. Neutropenia means that there are fewer neutrophils than normal in your blood and many people with lymphoma have neutropenia at some point during treatment[i]. Febrile neutropenia means that you have a fever AND a

OPDIVO™ is the first and only immuno-oncology therapy in lung cancer in Canada, which uses the body's own immune system to fight cancer, offering improved survival to more patients MONTREAL, March 1, 2016 /CNW/ – Health Canada has approved OPDIVO™ (nivolumab) injection, the first and only immuno-oncology therapy (anti PD-1 agent) approved in Canada for the treatment of adult patients with locally advanced or metastatic

Mississauga, ON. (January 12, 2016) – Amgen Canada Inc., today announced that Health Canada has granted conditional* approval of BLINCYTO™ (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B precursor acute lymphoblastic leukemia (ALL). With this approval, BLINCYTO™ becomes the first Health Canada-approved bispecific CD19-directed CD3 T-cell engager (BiTE®) antibody construct product, and the first single-agent immunotherapy to be approved